Last reviewed · How we verify
GNC-038
At a glance
| Generic name | GNC-038 |
|---|---|
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (PHASE1, PHASE2)
- A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) (PHASE1, PHASE2)
- A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL (PHASE1, PHASE2)
- A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) (PHASE1, PHASE2)
- Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia (PHASE1)
- A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus (PHASE1)
- A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis (PHASE1)
- Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GNC-038 CI brief — competitive landscape report
- GNC-038 updates RSS · CI watch RSS
- Sichuan Baili Pharmaceutical Co., Ltd. portfolio CI